Safety, Tolerability, and Preliminary Efficacy Study of ALS-357 in Patients With Cutaneous Metastatic Melanoma

Status unconfirmed · Phase 1

Conditions studied: Melanoma

In brief

A phase I trial to evaluate the safety and tolerability of ALS-357 when administered for four weeks as a topical ointment, in escalating doses, to patients with cutaneous metastatic melanoma and to evaluate the effect of escalating doses of topically applied ALS-357 on histological remission of cutaneous metastatic melanoma and induction of apoptotic biomarkers.

Key facts

Study ID

NCT00701987

Run by

Advanced Life Sciences, Inc.

People needed

12

Starts

2008-06-01

Last updated by the study team

2010-02-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Study Participants must be 18 years or older.
• Study Participants must have 2 sites of cutaneous metastatic melanoma that can not be removed with surgery.
• Study Participants may have been previously treated with chemotherapy or immunotherapy but not with in 4 weeks of first dose of study treatment.

Where it is running

• Robert H. Lurie Comprehensive Cancer Center, Northwestern University — Chicago, Illinois, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.